Investor should be able to visualize the long term story behind the near term numbers. The validation which Neuland has got by being part of the potential block buster drug KARXT is very critical for its long term growth. The validation has come at an very opportune time when Indian companies are being looked upon as a CDMO partner and also as an alternate to Chinese companies.
Management has given conservative guidance of 20% growth for next 4 to 5 years from FY 2025-26 and FY 2024-25 has been projected as a year of consolidation. The KARXT growth was probably not factored in the estimates and projections and hence management may give some additional clarification on this .The quarterly results are going to be lumpy however the base figures are going to increase on a YOY basis.
I have discussed in my previous post also about the potential benefit of KARXT in Neuland future journey.
Disclosure : Invested for long term and views are biased.
| Subscribe To Our Free Newsletter |
